Agenda

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint Providership of Comagine Health and New Mexico Cancer Center Foundation. Comagine Health is accredited by the NMMS to provide continuing medical education for physicians.

 

Comagine Health designates this Live Event for a maximum of 5.25 AMA PRA Category 1 Credit(s) tm. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Track

Morning Sessions

7:00 – 8:00 AM – Registration, Breakfast, Networking & Exhibits

7:45 – 8:30 AMENHERTU Product Theater: Daiichi Sankyo, Inc. and Astra Zeneca (Dr. Melanie Sheen, Ochsner Health)

8:30 – 8:45 AMWelcome and Introduction

8:45 – 9:00 AMBreak

9:00 – 10:00 AMHER2+- Keynote (Dr. Joyce O’Shaughnessy, Texas Oncology & Panel Discussion Moderated by Dr. Annette Fontaine, New Mexico Cancer Center)

10:00 – 10:10 AMBreak

10:10 – 11:10 AMTriple Negative Breast Cancer (Dr. Bora Lim, University of Texas MD Anderson Cancer Center & Panel Discussion Moderated by Dr. Bernard Tawfik, University of New Mexico Health Sciences Center)

11:15 – 11:45 AMctDNA in the Management of Breast Cancer (Dr. Ursa Brown Glaberman, CHRISTUS Health & Panel Discussion Moderated by Dr. Katherine Sanchez, New Mexico Cancer Center)

11:45 AM - 12:45 PMLunch

11:55 AM - 12:20 PMProduct Theater: Natera

Afternoon Sessions

12:50 – 2:05 PMAxillary Management: Surgical and Radiation Oncology (Dr. Colleen Kerrigan, New Mexico Cancer Center/Health Specialists of New Mexico & Panel Discussion with Dr. Nicole Hill, Dr. Anna Maria De Costa and Dr. U. Chris Shukla, Moderated by Dr. Jackie Neumanitis, UNM Health Sciences Center )

2:05 – 2:10 PMBreak

2:10 – 3:10 PMHER+- (Dr. Alison Stopeck, Stony Brook Cancer Center & Panel Discussion Moderated by Dr. Sofia Palacio, New Mexico Cancer Center)

3:15 Closing Remarks

Your opinion matters. Take our short survey and let us know what worked, what didn’t, and how we can improve future symposiums.